Gulsen Tukenmez Demirci
Research Subjects
Research Interests
Gulsen Tukenmez Demirci has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Damlanur Sakiz
Pathology Department, Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey
7 shared publicationsIlknur Altunay
Department of Dermatology, Şişli Etfal Training and Research Hospital, Istanbul, Turkey
7 shared publicationsGuldehan Atis
Dermatology Department, Siyami Ersek Cardiovasculer Surgery Hospital, Istanbul, Turkey
6 shared publicationsIlknur Kivanc Altunay
Dermatology Department, Sisli Etfal Training and Research Hospital, Istanbul, Turkey
5 shared publicationsAsli Kucukunal
Department of Dermatology Sisli Etfal Training and Research Hospital Istanbul Turkey
4 shared publications- Asli Kucukunal
Department of Dermatology, Şişli Etfal Training and Research Hospital, Istanbul, Turkey
4 shared publications
Latest Publications
- Open Access
- 27 December 2022
- Published by Bulent Evcevit University in Batı Karadeniz Tıp Dergisi
- Vol. 6 (3) , 404-409
Do Choroidal Melanocytes Affect Choroidal Thickness in Patients with Newly Diagnosed Vitiligo?
Aim: Vitiligo is a chronic skin disease and considered to be an autoimmune, neural, and autocytotoxic pathophysiology in which mainly the melanocytes in the epidermis are focused and destroyed. Therefore, alterations in the choroid and retinal pigment epithelium are expected, and there are very few publications using modern technology in research of this subject. This study aimed to examine the optic disc, retinal nerve fiber layer (RNFL), and choroidal thickness in patients with vitiligo by spectral-domain optical coherence tomography (SD-OCT) as a prospective observational study. Material and Methods: This single-center prospective cross-sectional study included 40 eyes of 40 patients with vitiligo and 42 eyes of 42 healthy individuals. The RNFL thickness, choroidal thickness, and optic disc parameters (rim area, disc area, and cup volume) were compared between the two groups. Results: The study consisted of 21 female and 19 male in the vitiligo group, and 21 female and 21 male in controls; no difference was found in gender distribution between two groups (p=0.836). Vitiligo and control groups had similar optic disc parameters, and RNFL and choroidal thicknesses; so the differences in the mentioned parameters did not differ statistically (p>0.05 for all). Conclusion: Vitiligo patients’ optic disc parameters, and RNFL and choroidal thicknesses did not differ from those in healthy individuals. Based on unknown pathogenesis, the melanocytes at the choroidal region may have compensatory mechanisms in vitiligo.
- 27 December 2022
- Published by Bulent Evcevit University in Batı Karadeniz Tıp Dergisi
- Vol. 6 (3) , 404-409
Open AccessDo Choroidal Melanocytes Affect Choroidal Thickness in Patients with Newly Diagnosed Vitiligo?
Aim: Vitiligo is a chronic skin disease and considered to be an autoimmune, neural, and autocytotoxic pathophysiology in which mainly the melanocytes in the epidermis are focused and destroyed. Therefore, alterations in the choroid and retinal pigment epithelium are expected, and there are very few publications using modern technology in research of this subject. This study aimed to examine the optic disc, retinal nerve fiber layer (RNFL), and choroidal thickness in patients with vitiligo by spectral-domain optical coherence tomography (SD-OCT) as a prospective observational study. Material and Methods: This single-center prospective cross-sectional study included 40 eyes of 40 patients with vitiligo and 42 eyes of 42 healthy individuals. The RNFL thickness, choroidal thickness, and optic disc parameters (rim area, disc area, and cup volume) were compared between the two groups. Results: The study consisted of 21 female and 19 male in the vitiligo group, and 21 female and 21 male in controls; no difference was found in gender distribution between two groups (p=0.836). Vitiligo and control groups had similar optic disc parameters, and RNFL and choroidal thicknesses; so the differences in the mentioned parameters did not differ statistically (p>0.05 for all). Conclusion: Vitiligo patients’ optic disc parameters, and RNFL and choroidal thicknesses did not differ from those in healthy individuals. Based on unknown pathogenesis, the melanocytes at the choroidal region may have compensatory mechanisms in vitiligo.
- 25 December 2021
- Published by Bulent Evcevit University in Batı Karadeniz Tıp Dergisi
- Vol. 5 (3) , 501-504
COVID-19 Re-Enfekte Hastada Periorbital Herpes Zoster Duplex Bilateralis Birlikteliği
Amaç: Varicella-zoster virüsü (VZV) bir insan nörotrofik virüsüdür ve Herpes Zoster (HZ), önceden geçirilmiş bir suçiçeği enfeksiyonunu takiben VZV’nin dorsal kök gangliyonundaki latent durumundan yeniden aktive olduğunda ortaya çıkan bir enfeksiyondur. COVID-19 enfeksiyonunda yaygın ürtiker, suçiçeği benzeri papülo veziküler erüpsiyon, vaskülitik lezyonlar ve HZ gibi çeşitli deri bulgularına rastlandığı da gözlenmiştir. Bitişik olmayan iki dermatom tutulduğunda, tek taraflı etkilenirse herpes zoster duplex unilateralis; iki taraflı ise, bilateralis olarak adlandırılır. Olgu: 39 yaşında kadın hasta, yüksek ateş, halsizlik, öksürük, nefes darlığı ve her iki göz kapağında oluşan döküntüler nedeniyle kliniğimize başvurdu. Hastanın anamnezinden üç ay önce COVID-19 enfeksiyonu ve eşzamanlı olarak yüz felci geçirdiği öğrenildi. Dermatolojik muayenesi sonucunda iki taraflı üst göz kapağında yer alan eritemli zeminde grupe veziküler lezyonların HZ duplex bilateralis ile uyumlu olduğu düşünüldü. 14. Gün sonunda COVID-19 enfeksiyon bulgularının kaybolması ve deri lezyonlarının tamamen iyileşmesi üzerine hasta taburcu edildi. Sonuç: Olgumuz immunkompetan olmasına rağmen ikinci kez COVID-19 enfeksiyonu geçirirken üst göz kapaklarında HZ duplex bilateralis tanısı alması nedeniyle dikkat çekicidir. COVID-19 enfeksiyonu ile HZ dupleks bilateralis birlikteliği şimdiye kadar literatürde bildirilmemiştir. COVID -19 ile enfekte hastalarda HZ enfeksiyonunun sıradışı tutulumlar ile ortaya çıkabileceği göz ardı edilmemelidir.
- 25 December 2021
- Published by Bulent Evcevit University in Batı Karadeniz Tıp Dergisi
- Vol. 5 (3) , 501-504
COVID-19 Re-Enfekte Hastada Periorbital Herpes Zoster Duplex Bilateralis Birlikteliği
Amaç: Varicella-zoster virüsü (VZV) bir insan nörotrofik virüsüdür ve Herpes Zoster (HZ), önceden geçirilmiş bir suçiçeği enfeksiyonunu takiben VZV’nin dorsal kök gangliyonundaki latent durumundan yeniden aktive olduğunda ortaya çıkan bir enfeksiyondur. COVID-19 enfeksiyonunda yaygın ürtiker, suçiçeği benzeri papülo veziküler erüpsiyon, vaskülitik lezyonlar ve HZ gibi çeşitli deri bulgularına rastlandığı da gözlenmiştir. Bitişik olmayan iki dermatom tutulduğunda, tek taraflı etkilenirse herpes zoster duplex unilateralis; iki taraflı ise, bilateralis olarak adlandırılır. Olgu: 39 yaşında kadın hasta, yüksek ateş, halsizlik, öksürük, nefes darlığı ve her iki göz kapağında oluşan döküntüler nedeniyle kliniğimize başvurdu. Hastanın anamnezinden üç ay önce COVID-19 enfeksiyonu ve eşzamanlı olarak yüz felci geçirdiği öğrenildi. Dermatolojik muayenesi sonucunda iki taraflı üst göz kapağında yer alan eritemli zeminde grupe veziküler lezyonların HZ duplex bilateralis ile uyumlu olduğu düşünüldü. 14. Gün sonunda COVID-19 enfeksiyon bulgularının kaybolması ve deri lezyonlarının tamamen iyileşmesi üzerine hasta taburcu edildi. Sonuç: Olgumuz immunkompetan olmasına rağmen ikinci kez COVID-19 enfeksiyonu geçirirken üst göz kapaklarında HZ duplex bilateralis tanısı alması nedeniyle dikkat çekicidir. COVID-19 enfeksiyonu ile HZ dupleks bilateralis birlikteliği şimdiye kadar literatürde bildirilmemiştir. COVID -19 ile enfekte hastalarda HZ enfeksiyonunun sıradışı tutulumlar ile ortaya çıkabileceği göz ardı edilmemelidir.
- Open Access
- 30 August 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (10) , 3121-3127
Has the COVID‐19 pandemic changed attitudes and behaviors concerning cosmetic care and procedures among patients presenting to the dermatology outpatient clinic? A multicenter study with 1437 participants
Background The rate of cosmetic procedures and use of skincare products is considered to be affected during the pandemic period; however, this has not been investigated yet. Objective To determine whether the ongoing pandemic has changed people's habits related to skincare products and cosmetic procedures. Methods We conducted a multicenter survey study covering both private and public hospitals. Sociodemographic characteristics and clinical diagnoses of the patients were noted by dermatologists. A survey was used to determine the type and application areas of skincare products and cosmetic procedures before and during the pandemic, whether the patients were concerned about being infected, and any change in the make-up habits of female patients. Results Of the 1437 patients, 86.7% presented to the hospital due to dermatological complaints and 13.3% for cosmetic procedures. The rate of those that did not use skincare products was 0.05% before and 0.06% during the pandemic. Of the participants, 43.2% had undergone cosmetic procedures before and 38.1% during the pandemic. For both periods, the most frequent cosmetic procedure applied was laser epilation, followed by skincare treatment and chemical peeling. While undergoing these procedures, 34.9% of the patients were concerned about contracting coronavirus. Conclusion There was no significant difference in the use of skincare products and cosmetic procedures before and during the pandemic. The majority of the patients continued to undergo these procedures despite their fear of being infected. This shows that during the pandemic period, patients are concerned with their appearance and continue to undergo cosmetic procedures and pay attention to their skincare.
- 30 August 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (10) , 3121-3127
Open AccessHas the COVID‐19 pandemic changed attitudes and behaviors concerning cosmetic care and procedures among patients presenting to the dermatology outpatient clinic? A multicenter study with 1437 participants
Background The rate of cosmetic procedures and use of skincare products is considered to be affected during the pandemic period; however, this has not been investigated yet. Objective To determine whether the ongoing pandemic has changed people's habits related to skincare products and cosmetic procedures. Methods We conducted a multicenter survey study covering both private and public hospitals. Sociodemographic characteristics and clinical diagnoses of the patients were noted by dermatologists. A survey was used to determine the type and application areas of skincare products and cosmetic procedures before and during the pandemic, whether the patients were concerned about being infected, and any change in the make-up habits of female patients. Results Of the 1437 patients, 86.7% presented to the hospital due to dermatological complaints and 13.3% for cosmetic procedures. The rate of those that did not use skincare products was 0.05% before and 0.06% during the pandemic. Of the participants, 43.2% had undergone cosmetic procedures before and 38.1% during the pandemic. For both periods, the most frequent cosmetic procedure applied was laser epilation, followed by skincare treatment and chemical peeling. While undergoing these procedures, 34.9% of the patients were concerned about contracting coronavirus. Conclusion There was no significant difference in the use of skincare products and cosmetic procedures before and during the pandemic. The majority of the patients continued to undergo these procedures despite their fear of being infected. This shows that during the pandemic period, patients are concerned with their appearance and continue to undergo cosmetic procedures and pay attention to their skincare.
- Open Access
- 27 August 2021
- Published by Galenos Yayinevi in Üroonkoloji Bülteni
- Vol. 20 (3) , 186-188
A Case of Eccrine Porocarcinoma Accompanying Renal Cell Carcinoma
- 27 August 2021
- Published by Galenos Yayinevi in Üroonkoloji Bülteni
- Vol. 20 (3) , 186-188
Open AccessA Case of Eccrine Porocarcinoma Accompanying Renal Cell Carcinoma
- Open Access
- 23 March 2021
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 87 (2) , 281-284
Rapid onset acquired progressive kinking of the hair: Scanning electron microscopic findings in a woman
- 23 March 2021
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 87 (2) , 281-284
Open AccessRapid onset acquired progressive kinking of the hair: Scanning electron microscopic findings in a woman
- 1 November 2020
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (6) , e14348
A case of elephantiasis nostras verrucosa treated successfully by a new type of compressive garment
Elephantiasis nostras verrucosa (ENV) is a clinical manifestation composed of hyperkeratotic, verrucous, and papillomatous lesions and dermal fibrosis, which complicate chronic lymphedema. There is currently no cure for ENV, however, several measures have been used to reduce lymphedema and the resultant pseudoepidermal hyperplasia. Supportive dressings and compression therapy still constitute an important part of the treatment. In this report, we present a 69-year-old male patient with ENV developed due to chronic lymphedema caused by venous insufficiency. After failure of healing with conventional two- and three-layered bandages, and elastic stockings, he was successfully treated by a new type of compression garment. We recommend this user friendly garment for prevention of frictional trauma, contact dermatitis, and secondary infection, which all may complicate compression treatments.
- 1 November 2020
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (6) , e14348
A case of elephantiasis nostras verrucosa treated successfully by a new type of compressive garment
Elephantiasis nostras verrucosa (ENV) is a clinical manifestation composed of hyperkeratotic, verrucous, and papillomatous lesions and dermal fibrosis, which complicate chronic lymphedema. There is currently no cure for ENV, however, several measures have been used to reduce lymphedema and the resultant pseudoepidermal hyperplasia. Supportive dressings and compression therapy still constitute an important part of the treatment. In this report, we present a 69-year-old male patient with ENV developed due to chronic lymphedema caused by venous insufficiency. After failure of healing with conventional two- and three-layered bandages, and elastic stockings, he was successfully treated by a new type of compression garment. We recommend this user friendly garment for prevention of frictional trauma, contact dermatitis, and secondary infection, which all may complicate compression treatments.
- 18 May 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (1) , 346-351
The investigation of the amounts and expressions of epidermal growth factor, epidermal growth factor receptor, and epidermal growth factor receptor gene polymorphisms in acne vulgaris
Background: Epidermal growth factor receptor inhibitors (EGFRI) used in cancer chemotherapy cause acneiform folliculitis in 70%‐100% of patients in a dose‐dependent manner. Acneiform folliculitis is considered to be caused by an inflammatory process due to follicular hyperkeratosis and subsequently a set of changes both in epidermis and hair follicles as a result of epidermal growth factor receptor (EGFR) blockade. Both acne vulgaris and acneiform folliculitis due to EGFRIs show similar changes in the pilosebaceous unit. Furthermore, in both groups of patients, topical application of recombinant human epidermal growth factor (EGF) has been reported to improve the disease.Aims: In this study, it was aimed to investigate the role of EGF and EGFR amount, expression, and EGFR gene polymorphisms in the etiopathogenesis of acne vulgaris.Patients/Methods: 156 acne vulgaris patients, within 18‐25 years of age, who had 15 or more inflammatory acne lesions on dermatologic evaluation were included in this study. The absence of any known systemic or genetic disease or cancer and any systemic or topical treatment for the last 1 month were prerequisites. In the control group, 154 volunteers in the same age range who were examined at the outpatient clinic with diagnoses of melanocytic nevus, ephelid, cherry angioma, and callus and who had no more than 3 inflammatory acne lesions were recruited. The amounts of EGF and EGFR were determined by sandwich ELISA, expressions of EGF and EGFR by reverse transcriptase polymerase chain reaction; EGFR polymorphisms were examined by restriction enzyme digestion, Sanger, and high‐resolution melting methods.Results: The patient and control groups were compared in terms of EGFR gene polymorphisms in addition to the amount and expressions of EGF and EGFR. The amount of EGF in the serum was found to be significantly higher in the acne group. (P = .0012). There was no significant difference in other parameters studied.Conclusion: The results of our study showed a significant increase in the amount of EGF in the acne group. Though EGF may be incriminated in the etiopathogenesis of AV, the most likely explanation about its role may be controlling inflammation from the very first stage.
- 18 May 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (1) , 346-351
The investigation of the amounts and expressions of epidermal growth factor, epidermal growth factor receptor, and epidermal growth factor receptor gene polymorphisms in acne vulgaris
Background: Epidermal growth factor receptor inhibitors (EGFRI) used in cancer chemotherapy cause acneiform folliculitis in 70%‐100% of patients in a dose‐dependent manner. Acneiform folliculitis is considered to be caused by an inflammatory process due to follicular hyperkeratosis and subsequently a set of changes both in epidermis and hair follicles as a result of epidermal growth factor receptor (EGFR) blockade. Both acne vulgaris and acneiform folliculitis due to EGFRIs show similar changes in the pilosebaceous unit. Furthermore, in both groups of patients, topical application of recombinant human epidermal growth factor (EGF) has been reported to improve the disease.Aims: In this study, it was aimed to investigate the role of EGF and EGFR amount, expression, and EGFR gene polymorphisms in the etiopathogenesis of acne vulgaris.Patients/Methods: 156 acne vulgaris patients, within 18‐25 years of age, who had 15 or more inflammatory acne lesions on dermatologic evaluation were included in this study. The absence of any known systemic or genetic disease or cancer and any systemic or topical treatment for the last 1 month were prerequisites. In the control group, 154 volunteers in the same age range who were examined at the outpatient clinic with diagnoses of melanocytic nevus, ephelid, cherry angioma, and callus and who had no more than 3 inflammatory acne lesions were recruited. The amounts of EGF and EGFR were determined by sandwich ELISA, expressions of EGF and EGFR by reverse transcriptase polymerase chain reaction; EGFR polymorphisms were examined by restriction enzyme digestion, Sanger, and high‐resolution melting methods.Results: The patient and control groups were compared in terms of EGFR gene polymorphisms in addition to the amount and expressions of EGF and EGFR. The amount of EGF in the serum was found to be significantly higher in the acne group. (P = .0012). There was no significant difference in other parameters studied.Conclusion: The results of our study showed a significant increase in the amount of EGF in the acne group. Though EGF may be incriminated in the etiopathogenesis of AV, the most likely explanation about its role may be controlling inflammation from the very first stage.
- 13 January 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (9) , 2339-2341
The efficacy and safety of high‐intensity focused ultrasound on upper arm laxity treatment: Our experience with five patients
Background: High‐intensity focused ultrasound is approved by FDA for both upper face and lower face, neck laxity and for decollete rejuvenation. It produces micro‐focused thermal damage on the dermis and superficial muscular aponeurotic system layer at precise depth and with this thermal stimulus the collagen denaturation and subsequent neo‐collagenosis occur. High‐intensity focused ultrasound (HIFU) effects on body laxity has also been used in some studies but it has not been approved yet.Aims: To find out the efficacy of HIFU for the treatment of upper under arm laxity.Patients/Methods: We used HIFU device with the new transducers; 13 mm depth 4 MHz and 2J for under arm laxity for 5 patients.Results: All patients showed a clinical improvement according to the physicians and patients assessment scales. The side effects were mild erythema and edema during the treatment and tenderness which lasted in 10 days. We follow up our patients in a one year period, and there were no side effects.Conclusion: HIFU can be used for upper arm laxity treatment with the new transducers developed for body areas.
- 13 January 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (9) , 2339-2341
The efficacy and safety of high‐intensity focused ultrasound on upper arm laxity treatment: Our experience with five patients
Background: High‐intensity focused ultrasound is approved by FDA for both upper face and lower face, neck laxity and for decollete rejuvenation. It produces micro‐focused thermal damage on the dermis and superficial muscular aponeurotic system layer at precise depth and with this thermal stimulus the collagen denaturation and subsequent neo‐collagenosis occur. High‐intensity focused ultrasound (HIFU) effects on body laxity has also been used in some studies but it has not been approved yet.Aims: To find out the efficacy of HIFU for the treatment of upper under arm laxity.Patients/Methods: We used HIFU device with the new transducers; 13 mm depth 4 MHz and 2J for under arm laxity for 5 patients.Results: All patients showed a clinical improvement according to the physicians and patients assessment scales. The side effects were mild erythema and edema during the treatment and tenderness which lasted in 10 days. We follow up our patients in a one year period, and there were no side effects.Conclusion: HIFU can be used for upper arm laxity treatment with the new transducers developed for body areas.
- Open Access
- 31 January 2018
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 8 (1) , 7-11
An unusual lesion on the nose: microvenular hemangioma
Microvenular hemangioma (MVH) is an acquired, benign type of hemangioma that usually manifests itself as a solitary, slowly growing, red to violaceous, asymptomatic papule, plaque or nodule. It is typically located on the trunk or extremities of young adults. It can be difficult to differentiate MVH from other types of hemangioma and Kaposi sarcoma. Herein we report a case of MVH unusual for its location, age of onset, and morphologic features. A 62-year-old man complained of an asymptomatic, bluish-red discoloration on the tip of his nose that had been present for two years. Dermatologic examination showed a violaceous patch 2 × 2 cm in diameter with indistinct borders. Incisional biopsy revealed irregularly branched small or medium-sized vascular spaces lined with benign endothelial cells, positive for CD34 and negative for HHV-8. MVH is a rare lesion, and less than 70 cases have been published to date. A review of 40 reported cases revealed that 15% of MVH patients were over 40 years of age and only 3% of the cases showed macules or patches. A literature survey showed only two cases of MVH located on the facial region, one on the chin and the other on the cheek. Our case was unique for its location and interesting for other rarely encountered features. MVH should be considered in the differential diagnoses of vascular lesions on nasal skin.
- 31 January 2018
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 8 (1) , 7-11
Open AccessAn unusual lesion on the nose: microvenular hemangioma
Microvenular hemangioma (MVH) is an acquired, benign type of hemangioma that usually manifests itself as a solitary, slowly growing, red to violaceous, asymptomatic papule, plaque or nodule. It is typically located on the trunk or extremities of young adults. It can be difficult to differentiate MVH from other types of hemangioma and Kaposi sarcoma. Herein we report a case of MVH unusual for its location, age of onset, and morphologic features. A 62-year-old man complained of an asymptomatic, bluish-red discoloration on the tip of his nose that had been present for two years. Dermatologic examination showed a violaceous patch 2 × 2 cm in diameter with indistinct borders. Incisional biopsy revealed irregularly branched small or medium-sized vascular spaces lined with benign endothelial cells, positive for CD34 and negative for HHV-8. MVH is a rare lesion, and less than 70 cases have been published to date. A review of 40 reported cases revealed that 15% of MVH patients were over 40 years of age and only 3% of the cases showed macules or patches. A literature survey showed only two cases of MVH located on the facial region, one on the chin and the other on the cheek. Our case was unique for its location and interesting for other rarely encountered features. MVH should be considered in the differential diagnoses of vascular lesions on nasal skin.
- Open Access
- 3 January 2018
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Endocrinology and Metabolism
- Vol. 22 (3) , 198-203
Two Cases of Bullous Pemphigoid Induced by Vildagliptin
Purpose: Bullous pemphigoid is an autoimmune blistering disorder that commonly develops in elderly subjects who are prone to an increased risk of mortality and morbidity. Although a few cases of dipeptidyl peptidase-4 inhibitors have been reported earlier, the etiology of bullous pemphigoid is not entirely clear. Case Report 1: An 81-years-old man presented with bullous pemphigoid after 28 months of treatment with repaglinide, vildagliptin, and metformin. Since his skin lesions were not improving with topical treatment of clobetasol propionate 0.05% ointment, so then he was started on methylprednisolone and azathioprine; however, the skin lesions sustained even then. Remission was achieved only after the withdrawal of vildagliptin. Case Report 2: A 64-years old man who was on insulin glargine, insulin aspart, and vildagliptin for 12 months, presented with BP of skin and laryngeal mucosa. The skin lesions were resolved after discontinuation of vildagliptin, but the laryngeal involvement continued to exist. Methylprednisolone and azathioprine treatment, for mucosal lesions, were started and continued for six months. Conclusion: Only a few cases of gliptin induced bullous pemphigoid are present in the literature. One of our cases is the first to demonstrate the latest onset of vildagliptin associated skin reactions while the other case is the first to demonstrate vildagliptin associated mucosal involvement. The exact mechanism of these reactions is unknown, however, it is proposed that it could be caused by modified immune responses. Our cases support the finding that there is a risk of bullous pemphigoid development in patients exposed to vildagliptin. Therefore, it is important to be aware of this risk and stop the vildagliptin treatment in such patients.
- 3 January 2018
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Endocrinology and Metabolism
- Vol. 22 (3) , 198-203
Open AccessTwo Cases of Bullous Pemphigoid Induced by Vildagliptin
Purpose: Bullous pemphigoid is an autoimmune blistering disorder that commonly develops in elderly subjects who are prone to an increased risk of mortality and morbidity. Although a few cases of dipeptidyl peptidase-4 inhibitors have been reported earlier, the etiology of bullous pemphigoid is not entirely clear. Case Report 1: An 81-years-old man presented with bullous pemphigoid after 28 months of treatment with repaglinide, vildagliptin, and metformin. Since his skin lesions were not improving with topical treatment of clobetasol propionate 0.05% ointment, so then he was started on methylprednisolone and azathioprine; however, the skin lesions sustained even then. Remission was achieved only after the withdrawal of vildagliptin. Case Report 2: A 64-years old man who was on insulin glargine, insulin aspart, and vildagliptin for 12 months, presented with BP of skin and laryngeal mucosa. The skin lesions were resolved after discontinuation of vildagliptin, but the laryngeal involvement continued to exist. Methylprednisolone and azathioprine treatment, for mucosal lesions, were started and continued for six months. Conclusion: Only a few cases of gliptin induced bullous pemphigoid are present in the literature. One of our cases is the first to demonstrate the latest onset of vildagliptin associated skin reactions while the other case is the first to demonstrate vildagliptin associated mucosal involvement. The exact mechanism of these reactions is unknown, however, it is proposed that it could be caused by modified immune responses. Our cases support the finding that there is a risk of bullous pemphigoid development in patients exposed to vildagliptin. Therefore, it is important to be aware of this risk and stop the vildagliptin treatment in such patients.